In-Hospital Cardiac Arrests and Resuscitation
A multi-centre observational study was conducted to report the duration of resuscitation for patients after an in-hospital cardiac arrest as well as to examine the relationship between resuscitation and neurologically intact survival to discharge.
See Also: ESA2016: Death by Resuscitation?
For the purpose of the study, the authors collated data from 40,563 non-survivors of in-hospital cardiac arrest in 573 hospitals. Patients were categorised on the basis of their chance of neurologically intact survival to hospital discharge. The categories were determined on the basis of the "Good Outcome Following Attempted Resuscitation" (GO-FAR) score which considers 13 pre-cardiac-arrest characteristics.
Findings show that the median duration of resuscitation effort was 19 min. The researchers found a correlation between median resuscitation duration and predicted chance of neurologically-intact survival. Those who received resuscitation for 7 min longer than the median had an above-average chance of neurologically-intact survival as compared to those who received a 16 min resuscitation.
The study also showed a wide variation in resuscitation practices. Approximately 40.4 percent of patients who had a very low chance of survival were resuscitated for longer than 19 min while 31.9 percent patients who had an above-average chance of survival were resuscitated for shorter than the median duration. These findings suggest that futile and prolonged resuscitation is being performed on a large number of patients while there are patients who are being withdrawn from life-saving resuscitation too soon.
Factors such as age, malignancy and existing heart failure were found to be correlated with below-median resuscitation in patients with above-average chance of neurologically-intact survival while factors such as shockable rhythm correlated with above-median resuscitation in patients with a very low chance of neurologically-intact survival. It thus appears that physicians may be placing emphasis on certain attributes and the decisions they are making may not be in the patient's best interest.
While the GO-FAR score may be a useful tool but it remains to be seen whether the model is effective enough to help physicians make accurate decisions regarding resuscitation. Patient preferences and concerns may play a role in resuscitation decisions and family members could also have an impact.
Overall, it is important to note that there are neurologically-intact survivors that are dying due to premature decisions to stop resuscitation. Using tools such as the GO-FAR score may be useful in making such decisions. Nevertheless, physicians need to look at the broader picture and consider all important factors before deciding whether to stop or continue resuscitation.
Image Credit: Wikimedia Commons
Published on : Tue, 31 Jan 2017
User experience enhanced by leading technologies With state-of-the-art screen technology, BeneVision N-Series patient monitors deliver clear, multi-color, wide-format displays for users to capture and review information at a glance. With...
The fully featured ICU ventilator, HAMILTON-MR1, guarantees uncompromised continuous ventilation care from the ICU to the MRI scanner and back. Its reliability and high performance, with advanced lung-protective strategies and patient-adaptive modes,...
NovaPort cannulas are designed specially to meet the needs of extracorporeal lung and heart support circuits and perioperative perfusion in minimally invasive heart surgery. All blood-contact surfaces of the NovaPort cannulas are coated with the bio-...
The HAMILTON-C1 neo is a versatile neonatal ventilator that combines invasive and noninvasive modes with the additional options of nCPAP and high flow oxygen therapy. The integrated turbine allows it to be operated independently of a compressed air supply....
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...